What is Incyte Corporation's stock symbol?
Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."
Where is Incyte Corporation's stock going? Where will Incyte Corporation's stock price be in 2017?
18 analysts have issued 12-month target prices for Incyte Corporation's shares. Their forecasts range from $85.00 to $149.00. On average, they expect Incyte Corporation's stock price to reach $122.56 in the next twelve months.
When will Incyte Corporation announce their earnings?
Incyte Corporation is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.
What are analysts saying about Incyte Corporation stock?
Here are some recent quotes from research analysts about Incyte Corporation stock:
According to Zacks Investment Research, "Although Incyte’s fourth-quarter results were positive beating on both the top and bottom line, Incyte is highly dependent on the single product, Jakafi, for growth which has its inherent risks. In addition, Jakafi could face competition from generic products. While we are positive on the company’s efforts to expand Jakafi’s label, any development/regulatory setback could pull down the stock significantly. Also, most of its pipeline candidates are in early-to-mid stages of development, and hence are expected to take time before being approved for use. Iclusig also faces intense competition. Approved treatments include Novartis’ Gleevec/Glivec, Bristol-Myers’ Sprycel and Pfizer’s Bosulif among others. On the other hand, shares of the company have outperformed that of the industry in the past one year." (2/17/2017)
- Jefferies Group LLC analysts commented, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and increasing depth from the maturing pipeline building towards broad, more diversified long-term growth opportunities. We continue to see upside potential in 2017 supported by continued Jakafi execution, IDO data/progress, and bari launch enthusiasm, with scarcity value likely continuing to drive M&A speculation. Adjust tgt to $140 from $136." (2/15/2017)
Brean Capital analysts commented, "US Jakafi sales of $183.3 million and 1Q16 total revenue of $263.5 million were in line with consensus of $183.6 million and $264 million, respectively. Ex-US Jakafi royalties of $21.9 million was also in line with consensus of $22.3 million. Incyte reported GAAP EPS of $0.12, versus consensus of $0.20, largely due to the $35 million milestone paid to Eli Lilly for GvHD rights to ruxolitinib. More importantly, Incyte updated full-year 2016 Jakafi US sales guidance to a new range $815-830 million from $800-815 million in order to better capture continued momentum in Jakafi revenue, and provided additional revenue guidance of $25-30 million for newly inlicensed Iclusig. We are encouraged by the robust volume growth in Jakafi revenue during 1Q16, offset by typical higher gross-to-net adjustment in 1Q16 due to the Medicare Part D donut hole. Incyte announced the acquisition of Ariad’s EU operations and an exclusive license to develop and commercialize Iclusig in the EU and 22 other countries. Following its discontinuance of the ruxolitinib JANUS program in metastatic pancreatic cancer and other trials, we view it as wise to purchase an approved product adding immediate revenue as well as coming with additional market potential. Incyte currently has 14 molecules in clinical development against 11 targets." (5/10/2016)
Who owns Incyte Corporation stock?
Incyte Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sands Capital Management LLC (1.94%), State Street Corp (1.91%), Shelton Capital Management (1.91%), Franklin Resources Inc. (1.57%), FMR LLC (1.47%) and Brown Capital Management LLC (1.40%). Company insiders that own Incyte Corporation stock include Barry A Ariko, Barry P Flannelly, Eric H Siegel, James M Daly, Julian Baker, Laurent Chardonnet, Paul A Friedman, Paula J Swain, Reid M Huber, Richard S Levy and Yao Wenqing.
Who sold Incyte Corporation stock? Who is selling Incyte Corporation stock?
Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Credit Agricole S A, Sands Capital Management LLC, Janus Capital Management LLC, State Street Corp, Calamos Advisors LLC, RTW Investments LP and Oxford Asset Management. Company insiders that have sold Incyte Corporation stock in the last year include Barry P Flannelly, Paula J Swain and Reid M Huber.
Who bought Incyte Corporation stock? Who is buying Incyte Corporation stock?
Incyte Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Shelton Capital Management, Fred Alger Management Inc., Federated Investors Inc. PA, Viking Global Investors LP, Asset Management One Co. Ltd., Marshall Wace LLP, Franklin Resources Inc. and Frontier Capital Management Co. LLC.
How do I buy Incyte Corporation stock?
Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Incyte Corporation stock cost?
One share of Incyte Corporation stock can currently be purchased for approximately $131.21.